Inicio>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>WYE-687 dihydrochloride

WYE-687 dihydrochloride

Catalog No.GC38473

El diclorhidrato de WYE-687 es un inhibidor de mTOR competitivo con ATP con una IC50 de 7 nM. El diclorhidrato de WYE-687 inhibe simultÁneamente la activaciÓn de mTORC1 y mTORC2. WYE-687 también inhibe PI3Kα y PI3Kγ con IC50 de 81 nM y 3,11 μM, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

WYE-687 dihydrochloride Chemical Structure

Cas No.: 1702364-87-1

Tamaño Precio Disponibilidad Cantidad
1mg
245,00 $
Disponible
2mg
428,00 $
Disponible
5mg
734,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM[1]. WYE-687 dihydrochloride concurrently inhibits activation of mTORC1 and mTORC2[2]. WYE-687 also inhibits PI3Kα and PI3Kγ with IC50s of 81 nM and 3.11 μM, respectively[1].

[1]. Yu K, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 1;69(15):6232-40. [2]. Cheng F, et al. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent. Biochem Biophys Res Commun. 2016 Feb 5;470(2):324-330.

Reseñas

Review for WYE-687 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WYE-687 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.